Condition: Healthy Adult Participants · Sponsor: Pharmosa Biopharm Inc.
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
This description comes directly from the study's public registry record.
Pei Kan, PhD · +886-2-2782-7561 · peikan@pharmosa.com.tw
Sydney Chuang · +886-2-2782-7561 · sydney@pharmosa.com.tw
Always discuss trial participation with your own doctor first.
| NZCR Ltd (New Zealand Clinical Research) | Christchurch, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06429930